Compare SPRO & WALD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | WALD |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United Kingdom |
| Employees | N/A | 364 |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 179.6M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | WALD |
|---|---|---|
| Price | $2.20 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 1.6M | 660.1K |
| Earning Date | 05-13-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | $9.89 |
| Revenue Next Year | $300.00 | $4.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.80 | $0.72 |
| 52 Week High | $3.09 | $3.22 |
| Indicator | SPRO | WALD |
|---|---|---|
| Relative Strength Index (RSI) | 36.21 | 52.11 |
| Support Level | $2.19 | $1.51 |
| Resistance Level | $2.47 | $1.95 |
| Average True Range (ATR) | 0.26 | 0.21 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 22.29 | 53.33 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.